Total
0
Shares
Patrys (ASX:PAB) - CEO and Managing Director, Dr James Campbell
CEO and Managing Director, Dr James Campbell
Source: Patrys Limited
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Non-clinical study finds Patrys’ (PAB) PAT-DX1 candidate can cross the blood-brain barrier in an animal model of primary brain cancer
  • Patrys says this is the first time the full-sized deoxymab, PAT-DX3, has been confirmed to cross the blood-brain barrier
  • Deoxymab has the ability to penetrate into cancer cell nuclei which allows it to bind and inhibit the DNA repair process
  • Patrys Chief Executive Officer and Managing Director Dr James Campbell says this discovery opened up a range of new opportunities for PAT-DX3
  • Patrys shares were up 15.7 per cent and trading at5.9 cents

A non-clinical study has found Patrys’ (PAB) PAT-DX1 candidate can cross the blood-brain barrier in an animal model of primary brain cancer.

The company said this is the first time the full-sized deoxymab, PAT-DX3, has been able to cross the blood-brain barrier, which had not previously been established due to its size.

This finding adds to previous studies which found PAT-DX1, a deoxymab
antibody fragment, was able to cross the blood-brain barrier in animal models of both primary and secondary brain cancer.

According to PAD, Deoxymab has the ability to penetrate into cancer cell nuclei which allows it to bind and inhibit the DNA repair process.

In terms of next steps, Patrys said it intends to follow up the discovery with studies to compare the effects of PAT-DX3 and PAT-DX1 on tumour reduction and survival in further primary and secondary brain cancer models.

Patrys Chief Executive Officer and Managing Director Dr. James Campbell said this discovery opened up a range of new opportunities for PAT-DX3.

“As PAT-DX3 shares a common mechanism of action with PAT-DX1, it is expected that it will also localise to both primary and secondary tumours in the brain and selectively kill cancer cells by blocking their DNA Damage Repair systems,” he said.

“While Patrys remains focused on preparing for its first-in-human study of PAT-DX1, it is clear that PAT-DX3 is a valuable addition to the Company’s deoxymab antibody platform.”

Patrys shares were up 15.7 per cent and trading at5.9 cents at 11:08 am AEST.

PAB by the numbers
More From The Market Herald
(ASX:ATH) -

" Alterity Therapeutics (ASX:ATH) expands clinical development program

Alterity Therapeutics (ATH) is expanding the phase two clinical development program for its lead asset ATH434 in patients with Multiple System Atrophy (MSA).
Althea Group (ASX:AGH) - CEO, Joshua Fegan

" Althea Group (ASX:AGH) hits new high in sales receipts

Althea Group (AGH) brought in a new high of $4.5 million in customer receipts over the recently completed September quarter.
Singular Health Group (ASX:SHG) - Chief Operating Officer, James Hill

" Singular Health (ASX:SHG) collaborates with CSIRO and Osteopore (ASX:OSX)

Singular Health Group (SHG) will collaborate with CSIRO and Osteopore (OSX) for an artificial intelligence (AI) based tool to make patient-specific 3D cranial
ImpediMed (ASX:IPD) - MD and CEO, Richard Carreon

" ImpediMed (ASX:IPD) completes lymphoedema prevention trial

ImpediMed (IPD) has rounded off its PREVENT trial, successfully meeting its primary end point.